BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

367 related articles for article (PubMed ID: 28928091)

  • 1. P2Y
    Hensch NR; Karim ZA; Pineda J; Mercado N; Alshbool FZ; Khasawneh FT
    Biochem Biophys Res Commun; 2017 Nov; 493(2):1069-1074. PubMed ID: 28928091
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Characterization of a novel function-blocking antibody targeted against the platelet P2Y1 receptor.
    Karim ZA; Vemana HP; Alshbool FZ; Lin OA; Alshehri AM; Javaherizadeh P; Paez Espinosa EV; Khasawneh FT
    Arterioscler Thromb Vasc Biol; 2015 Mar; 35(3):637-44. PubMed ID: 25593131
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting of C-type lectin-like receptor 2 or P2Y12 for the prevention of platelet activation by immunotherapeutic CpG oligodeoxynucleotides.
    Delierneux C; Donis N; Servais L; Wéra O; Lecut C; Vandereyken M; Musumeci L; Rahmouni S; Schneider J; Eble JA; Lancellotti P; Oury C
    J Thromb Haemost; 2017 May; 15(5):983-997. PubMed ID: 28296036
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Synergistic Inhibition of Both P2Y1 and P2Y12 Adenosine Diphosphate Receptors As Novel Approach to Rapidly Attenuate Platelet-Mediated Thrombosis.
    Gremmel T; Yanachkov IB; Yanachkova MI; Wright GE; Wider J; Undyala VV; Michelson AD; Frelinger AL; Przyklenk K
    Arterioscler Thromb Vasc Biol; 2016 Mar; 36(3):501-9. PubMed ID: 26743169
    [TBL] [Abstract][Full Text] [Related]  

  • 5. SAR216471, an alternative to the use of currently available P2Y₁₂ receptor inhibitors?
    Delesque-Touchard N; Pflieger AM; Bonnet-Lignon S; Millet L; Salel V; Boldron C; Lassalle G; Herbert JM; Savi P; Bono F
    Thromb Res; 2014 Sep; 134(3):693-703. PubMed ID: 25064036
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Increased platelet activation and thrombosis in transgenic mice expressing constitutively active P2Y12.
    Zhang Y; Ye J; Hu L; Zhang S; Zhang SH; Li Y; Kunapuli SP; Ding Z
    J Thromb Haemost; 2012 Oct; 10(10):2149-57. PubMed ID: 22906019
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibitory Effect of Flavonolignans on the P2Y12 Pathway in Blood Platelets.
    Bijak M; Szelenberger R; Dziedzic A; Saluk-Bijak J
    Molecules; 2018 Feb; 23(2):. PubMed ID: 29439388
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Uridine Triphosphate Thio Analogues Inhibit Platelet P2Y
    Gündüz D; Tanislav C; Sedding D; Parahuleva M; Santoso S; Troidl C; Hamm CW; Aslam M
    Int J Mol Sci; 2017 Jan; 18(2):. PubMed ID: 28146050
    [TBL] [Abstract][Full Text] [Related]  

  • 9. GLS-409, an Antagonist of Both P2Y
    Smolensky Koganov E; Michelson AD; Yanachkov IB; Yanachkova MI; Wright GE; Przyklenk K; Frelinger AL
    Sci Rep; 2018 Sep; 8(1):14529. PubMed ID: 30266987
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The P2Y(12) antagonists, 2MeSAMP and cangrelor, inhibit platelet activation through P2Y(12)/G(i)-dependent mechanism.
    Xiang B; Zhang G; Ren H; Sunkara M; Morris AJ; Gartner TK; Smyth SS; Li Z
    PLoS One; 2012; 7(12):e51037. PubMed ID: 23236426
    [TBL] [Abstract][Full Text] [Related]  

  • 11. P2Y₁₂ and EP3 antagonists promote the inhibitory effects of natural modulators of platelet aggregation that act via cAMP.
    Iyú D; Glenn JR; White AE; Fox SC; Dovlatova N; Heptinstall S
    Platelets; 2011; 22(7):504-15. PubMed ID: 21591981
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The small-molecule MERTK inhibitor UNC2025 decreases platelet activation and prevents thrombosis.
    Branchford BR; Stalker TJ; Law L; Acevedo G; Sather S; Brzezinski C; Wilson KM; Minson K; Lee-Sherick AB; Davizon-Castillo P; Ng C; Zhang W; Neeves KB; Lentz SR; Wang X; Frye SV; Shelton Earp H; DeRyckere D; Brass LF; Graham DK; Di Paola JA
    J Thromb Haemost; 2018 Feb; 16(2):352-363. PubMed ID: 29045015
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ticagrelor effectively and reversibly blocks murine platelet P2Y12-mediated thrombosis and demonstrates a requirement for sustained P2Y12 inhibition to prevent subsequent neointima.
    Patil SB; Jackman LE; Francis SE; Judge HM; Nylander S; Storey RF
    Arterioscler Thromb Vasc Biol; 2010 Dec; 30(12):2385-91. PubMed ID: 21071697
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The effect of P2Y12 inhibition on platelet activation assessed with aggregation- and flow cytometry-based assays.
    Leunissen TC; Wisman PP; van Holten TC; de Groot PG; Korporaal SJ; Koekman AC; Moll FL; Teraa M; Verhaar MC; de Borst GJ; Urbanus RT; Roest M
    Platelets; 2017 Sep; 28(6):567-575. PubMed ID: 27885904
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Blockade of the purinergic P2Y12 receptor greatly increases the platelet inhibitory actions of nitric oxide.
    Kirkby NS; Lundberg MH; Chan MV; Vojnovic I; Solomon AB; Emerson M; Mitchell JA; Warner TD
    Proc Natl Acad Sci U S A; 2013 Sep; 110(39):15782-7. PubMed ID: 24003163
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects on platelet function of an EP3 receptor antagonist used alone and in combination with a P2Y12 antagonist both in-vitro and ex-vivo in human volunteers.
    Fox SC; May JA; Johnson A; Hermann D; Strieter D; Hartman D; Heptinstall S
    Platelets; 2013; 24(5):392-400. PubMed ID: 22866894
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A clopidogrel-insensitive inducible pool of P2Y12 receptors contributes to thrombus formation: inhibition by elinogrel, a direct-acting, reversible P2Y12 antagonist.
    Haberstock-Debic H; Andre P; Mills S; Phillips DR; Conley PB
    J Pharmacol Exp Ther; 2011 Oct; 339(1):54-61. PubMed ID: 21730013
    [TBL] [Abstract][Full Text] [Related]  

  • 18. New highly active antiplatelet agents with dual specificity for platelet P2Y1 and P2Y12 adenosine diphosphate receptors.
    Yanachkov IB; Chang H; Yanachkova MI; Dix EJ; Berny-Lang MA; Gremmel T; Michelson AD; Wright GE; Frelinger AL
    Eur J Med Chem; 2016 Jan; 107():204-18. PubMed ID: 26588064
    [TBL] [Abstract][Full Text] [Related]  

  • 19. G-protein-coupled receptors signaling pathways in new antiplatelet drug development.
    Gurbel PA; Kuliopulos A; Tantry US
    Arterioscler Thromb Vasc Biol; 2015 Mar; 35(3):500-12. PubMed ID: 25633316
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Is platelet inhibition correlated with time from last intake on P2Y12 blockers after an acute coronary syndrome? A pilot study.
    Deharo P; Quilici J; Bonnet G; Grosdidier C; Morange P; Alessi MC; Bonnet JL; Cuisset T
    Platelets; 2016 Dec; 27(8):791-795. PubMed ID: 27275528
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.